Mylan Fights For Invalidity Case In Neurim Melatonin Battle
Generic-drug maker Mylan has argued it shouldn't be blocked from challenging Neurim Pharmaceuticals Ltd.'s melatonin patent just because a London court previously upheld the parent patent for the insomnia medication, as...To view the full article, register now.
Already a subscriber? Click here to view full article